Evidence map›Paper›PMID 40255145›Full record

ReviewJournal of Crohn's & colitis2025

5-Aminosalicylates for non-surgical patients with active or quiescent Crohn's disease: an overview of systematic reviews (umbrella review).

Abdulaziz Alajmi, Yuhong Yuan, Virginia Solitano, Daniel Eli Cohen Rosenfeld, Maria Manuela Estevinho, Fernando Magro, Olga Maria Nardone, Vipul Jairath

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Abdulaziz AlajmiDepartment of Medicine, London Health Science Center, London, Ontario, Canada.
Yuhong YuanDepartment of Medicine, London Health Science Center, London, Ontario, Canada.ORCID 0000-0003-4374-3042
Virginia SolitanoGastroenterology and Endoscopy, IRCCS Hospital San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.ORCID 0000-0002-2935-6778
Daniel Eli Cohen RosenfeldWestern University, London, Ontario, Canada.
Maria Manuela EstevinhoDepartment of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.ORCID 0000-0001-7171-0139
Fernando MagroDepartment of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.ORCID 0000-0003-2634-9668
Olga Maria NardoneGastroenterology, Department of Public Health, University Federico II of Naples, Naples, Italy.
Vipul JairathDepartment of Medicine, London Health Science Center, London, Ontario, Canada.ORCID 0000-0002-1092-0033

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background5-aminosalicylates (5-ASAs) are commonly used in non-surgical patients with Crohn's disease (CD), especially in mild-to-moderate disease, despite current guidelines against their use. Despite this, the evidence regarding their efficacy is mixed, with conflicting findings in systematic reviews (SRs).

aimsWe conducted an overview of reviews (umbrella review) to consolidate existing knowledge from published SRs on using 5-ASAs in patients with active or quiescent CD.

methodsWe systematically searched for relevant SRs published in English until July 6, 2024, summarizing data on 5-ASAs used in induction, maintenance, or withdrawal trials of CD. We also searched for placebo-controlled RCTs of 5-ASAs published after 2015.

resultsEight SRs met our inclusion criteria, with the number of included RCTs of 5-ASAs in CD ranging from 2 to 22. Two were network meta-analyses (NMA); 4 were Cochrane SRs. SRs found no evidence of benefit for oral 5-ASAs over placebo for maintaining medically induced remission. The latest NMA in 2017, including 22 RCTs for induction of remission, suggested that high-dose mesalamine (≥ 2.4 g) was more effective than placebo, though ranking lower than systemic corticosteroid and high-dose budesonide. No placebo-controlled RCT of 5-ASAs was published after 2015, only the ongoing STATIC trial is investigating the withdrawal of 5-ASAs in patients with quiescent CD.

conclusionThis overview of SRs suggests that the evidence does not support the use of 5-ASAs for maintaining medically induced remission. However, high-dose mesalamine may be considered for inducing remission in selected patients with mild luminal CD who prefer to avoid steroids.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalCrohn DiseaseMesalamineHumansRandomized Controlled Trials as TopicRemission InductionSystematic Reviews as TopicAnti-Inflammatory Agents, Non-SteroidalMesalamine5-ASAsCrohn’s diseaseoverview of reviewsumbrella review

Identifiers

PMID40255145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.